Etomerzol during recovery from acute carbofos poisoning
Comparison in people · 1996
- What was studied
- 34 acute oral poisoning cases described. Four named study groups total 29: moderate 6 Etomerzol and 6 control, severe 9 Etomerzol and 8 control.
- Main finding
- The dissertation author reported normalized physical work capacity by days 7 vs 11 in moderate poisoning and days 10 vs 16 in severe poisoning. Pharmacokinetic estimates showed a longer half-life in the poisoning groups.
Reported findings and study design
Historical single-blind comparison of adjunctive Etomerzol and control care. Moderate poisoning: 6 vs 6. Severe poisoning: 9 vs 8. The report describes 34 cases but accounts for 29 in the four arms.
Population or model 34 acute oral poisoning cases described. Four named study groups total 29: moderate 6 Etomerzol and 6 control, severe 9 Etomerzol and 8 control.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported recovery of work capacity | Day 7 vs 11 (moderate) and day 10 vs 16 (severe) | Etomerzol vs control. Timing comes from the author’s conclusions. |
| Inspiratory breath-hold, moderate poisoning | 46.9 vs 38.5 seconds | Day 7 · p<0.05 as marked |
| Grip dynamometry, severe poisoning | 86.4% vs 67.3% | Reference for the percentages is unclear in the transcription. · Day 10 · p<0.05 as marked |
Etomerzol pharmacokinetics after carbofos poisoning (Table 7)
| Measure | Healthy (n=8) | Moderate poisoning (n=5) | Severe poisoning (n=6) |
|---|---|---|---|
| Estimated elimination half-life, hours | 2.08 | 9.00 | 7.78 |
| Estimated initial concentration, µg/mL | 7.01 | 25.68 | 48.10 |
The clinical exposure used to estimate these parameters and any overlap with the 29 comparison patients remain unclear.
These are results from a transcription of a historical author’s abstract. A full thesis scan is needed to confirm the treatment regimen, methods, and adverse events.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The author describes a single-blind comparison, but the allocation and masking procedures are not given. The four arm counts leave five of the 34 reported cases unaccounted for.
- The clinical methods do not specify the actual arm dosing. A proposed intramuscular schedule appears in the closing recommendations, where the concentration is garbled in the transcription. The rat protocol is distinct.
- The pharmacokinetic subset may overlap the clinical comparison. Shared authors and indications link the clinical conference papers to the same program. Original reports are needed to verify overlap and outcome definitions.
Related publications may describe some of the same participants or experiments.
Source details
Dissertation author’s abstract — third-party transcription
Author’s abstract transcription, clinical methods and Tables 2, 3 and 7; library catalogue confirms the document. Full thesis and scan unavailable.
Sources checked
Citation
I. V. Aksenov. Etomerzol during recovery from acute carbofos poisoning Kirov Military Medical Academy, St. Petersburg, 1996. Author’s abstract, library call number 1996/А 42.